Psoriasis – Talk Bio

J&J’s Oral IL-23 Drug Icotrokinra Surpasses Sotyktu in Phase 3 Psoriasis Trials

4 weeks ago talkbio0Tagged Dental Plaque, deucravacitinib, IL-23 receptor antagonist, JNJ-2113, Johnson & Johnson, Myers, oral peptide, Phase 3 clinical trial, Psoriasis, skin clearance, Sotyktu

Icotrokinra; JNJ-2113; Johnson & Johnson; IL-23 receptor antagonist; Sotyktu; deucravacitinib; plaque psoriasis; Phase 3 clinical trial; skin clearance; oral peptide; Bristol Myers Squibb

Junshi Biosciences Announces Phase 3 Win for IL-17A Drug JS005 in Psoriasis, Prepares China NDA Submission

1 month ago talkbio0Tagged Biosciences, China, clinical endpoints, Drug Approval, IL-17A monoclonal antibody, JS005, Junshi, Psoriasis

Junshi Biosciences; JS005; IL-17A monoclonal antibody; psoriasis; phase 3 trial; clinical endpoints; China drug approval

LEO Pharma Acquires Exclusive Global Rights for Boehringer Ingelheim’s Psoriasis Drug Spevigo in €90 Million Deal

3 months ago talkbio0Tagged Boehringer Ingelheim, Drug licensing, Generalized pustular psoriasis, IL1RAP protein, human, Immunology, News [Publication Type], Partnership, Pharma, Psoriasis, spesolimab, Spevigo

LEO Pharma; Boehringer Ingelheim; Spevigo; spesolimab; psoriasis; GPP; drug licensing; immunology; IL-36 receptor; partnership; biotech news

AbbVie Expands Immunology Pipeline with $200M Acquisition of Nimble Therapeutics

10 months ago talkbio0Tagged AbbVie, Autoimmune Diseases, IL23R gene, Immunology, Inhibitor, Nimble, Peptides, Psoriasis

AbbVie, Nimble Therapeutics, Immunology, Psoriasis, Autoimmune Diseases, IL23R Inhibitor, Peptide Therapeutics

J&J’s Icotrokinra (JNJ-2113) Achieves Significant Success in Phase 3 Trials for Moderate to Severe Plaque Psoriasis

11 months ago talkbio0Tagged Clinical Trials, Dental Plaque, IL-23 receptor antagonist, JNJ-2113, Phase, Protagonist Therapeutics, Psoriasis

JNJ-2113, icotrokinra, IL-23 receptor antagonist, plaque psoriasis, Phase 3 clinical trials, Johnson & Johnson, Protagonist Therapeutics

Skyrizi Surpasses Humira as AbbVie’s Top-Selling Drug

12 months ago talkbio0Tagged AbbVie, Arthritis, Psoriatic, Crohn 's disease, Dental Plaque, Humira, Immunology, Psoriasis, Skyrizi

Skyrizi, Humira, AbbVie, revenue leader, immunology, plaque psoriasis, psoriatic arthritis, Crohn’s disease

Organon Expands Dermatology Portfolio with $1.2B Acquisition of Dermavant and VTAMA Cream

1 year ago talkbio0Tagged Acquisition (action), Dairy Cream, Dental Plaque, Dermatitis, Atopic, Dermatology field, Dermavant, Organon, Psoriasis, steroid-free skin cream, Vtama

Organon, Dermavant, VTAMA cream, dermatology, acquisition, steroid-free skin cream, plaque psoriasis, atopic dermatitis

Organon Expands Dermatology Portfolio with Acquisition of Dermavant for Up to $1.2 Billion

1 year ago talkbio0Tagged Acquisition (action), Dairy Cream, Dental Plaque, Dermatitis, Atopic, Dermatology field, Dermavant, Organon, Psoriasis, Roivant, tapinarof, Vtama

Organon, Dermavant, Roivant, dermatology, VTAMA cream, tapinarof, plaque psoriasis, atopic dermatitis, acquisition

Ventyx Discontinues TYK2 Inhibitor Programme Following Second Mid-Stage Setback

1 year ago talkbio0Tagged Arthritis, Psoriatic, Biosciences, Crohn 's disease, Drug Development, Inflammatory disorder, Inhibitor, Phase 2 Failure, Psoriasis, TYK2 gene, Ventyx, VTX958

Ventyx Biosciences, TYK2 inhibitor, VTX958, Phase 2 failure, psoriasis, psoriatic arthritis, Crohn’s disease, inflammatory diseases, drug development.

Alumis Completes IPO, Raising $250 Million for Inflammation and Immunology Research

1 year ago talkbio0Tagged Alumis, biotech, Dental Plaque, Immunology, Inflammation, Inhibitor, IPO, Psoriasis, TYK2 gene, Uveitis

Alumis, IPO, Inflammation, Immunology, Biotech, TYK2 Inhibitor, Plaque Psoriasis, Uveitis, Lupus